The case for & against
Bull & Bear analysis
Bearish
Coherus Oncology, Inc. (NASDAQ: CHRS) is a biotechnology company that focuses on developing innovative cancer therapies, specifically within the PD-1 inhibitor market. The company is advancing its clinical pipeline, centered around its lead candidate, Lactorsi, which targets nasopharyngeal carcinoma and other solid tumors. Positioned within a high-growth oncology sector, Coherus aims to capture significant market share as it navigates competitive dynamics and regulatory environments.
Bull says
- ↑Q1 2026 Lactorsi revenue rose 61% YoY to $11.8M, fueled by a 21% increase in new patient starts.
- ↑Management projects Lactorsi will reach $15M quarterly by late 2026 and $175M in annual sales by 2028.
- ↑Promising pipeline includes CHS114 addressing PD-1 resistance, backed by J&J collaborations to advance clinical studies.
- ↑Strong market adoption: new patient starts up 21% and purchasing accounts at all-time highs in Q1.
- ↑Stock seems undervalued with high book-to-price ratio, strong growth potential, positive momentum, and favorable oil sensitivity.
- ↑Solid liquidity: $167M cash position and reduced R&D costs to $21.5M support upcoming clinical catalysts.
Bear says
- ↓June 2026 downgrade followed Q2 EPS estimate cut from $0.08 to -$0.12, undermining investor confidence.
- ↓Severe profitability challenges: negative earnings yield and weak profitability metrics highlight operational inefficiencies.
- ↓High volatility and elevated short interest signal market skepticism and potential for abrupt price swings.
- ↓Operational execution risks: severe weather disrupted Q1 patient cycles, risking future revenue continuity.
- ↓Balance sheet concerns and negative cash-flow prospects raise financial stability questions for long-term investors.
- ↓Competitive threats from Merck’s Keytruda and BMS’s Opdivo could limit Lactorsi’s market penetration.
Investment themes with CHRS
Biotech↑ +0.07%
Genetic and drug innovations driving medical breakthroughs
ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-12-2026neutral
Transcript signals
Bull points
- The key financial event this quarter was the follow-on equity offering, which we mentioned on last earnings call. As an update, total net proceeds were $54 million and include the full exercise of the underwriters over allotment option. These funds have strengthened our liquidity position and are supporting the new Tavno-Ketog CRC and prostate studies, Enhanced investments in Lactorsi commercialization capabilities to reach revenue targets faster and general corporate purposes.
- We believe we are sufficiently funded through key data rate outs in 2026 and 2027.
- Having the Cas-Do-Ketog HCC study fully enrolled now allows for the biomarker analysis to be done, prioritizing two aspects for data readouts, biomarkers associated with response and pharmacodynamic biomarkers to support contribution of effect for Casdoketag.
Bear points
- Total cash, cash equivalents and investments at the end of the quarter was $167 million, down slightly from $172.1 million at year end.
- Amgen halted enrollment in their program after presenting data showing only two responses and 77 patients treated.
- many CCR8 programs that are stopping are doing so due to drug-like properties falling short and failing the right drug criteria.
Read full transcript analysis ›